uniQure (QURE) Stock Research

Over a week ago

Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls

+11

Jul 30, 9:38 AM

uniQure price target lowered by $5 at Barclays, here's why

QURE

Jul 30, 5:25 AM

Wolfe upgrades uniQure to Outperform, sees 'clear path to approval' for AMT-130

QURE

Jul 29, 4:13 PM

Wolfe Research gets more bullish on uniQure, upgrades shares

QURE

Jul 29, 4:07 PM

uniQure reports Q2 EPS ($1.22), consensus (71c)

QURE

Jul 29, 7:27 AM

uniQure price target raised by $30 at H.C. Wainwright, here's why

QURE

Jun 29, 5:57 AM

uniQure price target raised by $33 at Mizuho, here's why

QURE

Jun 25, 7:21 AM

uniQure 4.95M share Spot Secondary priced at $45.50

QURE

Jun 23, 9:45 PM

uniQure rises 7.6%

QURE

Jun 23, 10:00 AM

uniQure announces $150M offering of common stock

QURE

Jun 22, 4:08 PM

Regenxbio tells WSJ that FDA will reverse rejection of drug

Jun 22, 6:38 AM

uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260

QURE

Jun 19, 7:21 AM

SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls

+13

Jun 18, 9:35 AM

ClearPoint Neuro price target raised to $30 from $20 at B. Riley

Jun 18, 8:55 AM

Barclays upgrades uniQure, calls BLA submission 'major positive'

QURE

Jun 18, 8:18 AM

uniQure price target raised by $34 at Leerink, here's why

QURE

Jun 18, 7:27 AM

uniQure price target raised by $30 at RBC Capital, here's why

QURE

Jun 18, 7:12 AM

Barclays gets more bullish on uniQure, upgrades shares

QURE

Jun 18, 7:07 AM

uniQure price target raised by $32 at Goldman Sachs, here's why

QURE

Jun 18, 6:20 AM

What You Missed On Wall Street On Wednesday

+27

Jun 17, 4:09 PM

Midday Fly By: Jabil reports 'beat and raise,' Diana Shipping ups Genco offer

+23

Jun 17, 11:55 AM

uniQure upgraded to Overweight at Cantor Fitzgerald after BLA filing news

QURE

Jun 17, 11:46 AM

Cantor Fitzgerald gets more bullish on uniQure, upgrades shares

QURE

Jun 17, 11:41 AM

uniQure AMT-130 update 'materially positive,' says H.C. Wainwright

QURE

Jun 17, 9:14 AM

ClearPoint Neuro up 32% after uniQure announces plan for AMT-130 BLA submission

Jun 17, 8:36 AM

Approved Commercial Product: Hemgenix: uniQure has an FDA and EMA approved gene therapy, Hemgenix (etranacogene dezaparvovec), for hemophilia B, which is the world's first and only gene therapy for this condition, providing significant revenue potential and market validation for their platform.

Validated AAV Gene Therapy Platform: The company's proprietary AAV5 vector platform has been clinically validated through the approval of Hemgenix, demonstrating its efficacy and safety profile and providing a strong foundation for future pipeline candidates.

Integrated In-House Manufacturing Capabilities: uniQure possesses state-of-the-art in-house manufacturing facilities, which are critical for controlling the quality, cost, and supply chain of complex gene therapies from clinical development through commercialization.

Pipeline Clinical Development Failure Risk: uniQure's other pipeline candidates beyond Hemgenix face significant risks of failure in clinical trials, including issues with efficacy, safety, or study design, which could prevent them from reaching regulatory approval.

Regulatory Approval for Future Products Risk: While Hemgenix is approved, uniQure's other investigational gene therapies in its pipeline are subject to extensive and uncertain regulatory review processes by agencies worldwide, which may or may not result in approval.

Commercialization and Market Adoption Risk: Despite Hemgenix's approval, its high price, the complexity of market access, competition, and the challenges of securing broad reimbursement and physician adoption pose risks to its commercial success and revenue generation.